Johnson & Johnson or Bio-Techne Corporation: Who Manages SG&A Costs Better?

Who Manages SG&A Costs Better: Johnson & Johnson or Bio-Techne Corporation?

In the competitive landscape of the healthcare industry, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. Over the past decade, Johnson & Johnson and Bio-Techne Corporation have demonstrated contrasting approaches to handling these costs.

From 2014 to 2023, Bio-Techne Corporation's SG&A expenses surged by over 550%, reflecting its aggressive expansion strategy. In contrast, Johnson & Johnson, a giant in the pharmaceutical sector, maintained a relatively stable SG&A cost, with fluctuations of around 15% over the same period. This stability underscores Johnson & Johnson's efficient cost management practices, despite its massive scale.

Interestingly, the data for 2024 is incomplete, leaving room for speculation on future trends. As these companies continue to evolve, their ability to manage SG&A expenses will remain a key indicator of their operational efficiency and market competitiveness.